A Phase 1 interventional study of VH4527079 in HIV Infections, sponsored by ViiV Healthcare. Terminated at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Terminated for business reasons
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 159th largest by enrollment of the 210 interventional ones that give a count, is one of 11 that started in 2024, is one of 83 in phase 1, and was the 249th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in Romania, South Africa, Uganda
ViiV Healthcare · Sites in Netherlands
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 85 · Phase 2 53 · Phase 3 68 · Phase 4 18
First in 1994; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 82 across the 210 interventional studies, 328 across the 14 observational. Of the 230 that completed or were terminated, 95 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
6 of the studies in HIV Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
| NCT07934719ViiV HealthcareMass Balance and Absolute Bioavailability of [14C]-VH4011499 | 2027-02-18 |
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
| NCT07939594ViiV HealthcareAn Evaluation of the Potential for VH4011499 Drug-drug-interactions | 2027-03-12 |
| NCT07525544ViiV HealthcareA Study to Investigate the Safety and PK of VH4770359 in Healthy Participants | 2027-05-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 266 studies in HIV Infections by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single dose administration of VH4527079 by subcutaneous (SC) injection or by intravenous (IV) infusion in healthy adult participants and multiple dose administration by IV infusion in healthy adult participants and in Persons with HIV (PWH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Participants who are female at birth are eligible to participate if at least one of the following conditions applies: Not pregnant or breastfeeding and, at least, one of the following conditions apply:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy adult participants receive a single dose of VH4527079 Dose 1 (lowest dose) by IV infusion.
Biological: VH4527079
Healthy adult participants receive a single dose of VH4527079 Dose 2 (low dose) by IV infusion.
Biological: VH4527079
Healthy adult participants receive a single dose of VH4527079 Dose 3 (mid-low dose) by IV infusion.
Biological: VH4527079
Healthy adult participants receive a single dose of VH4527079 Dose 4 (mid-high dose) by IV infusion.
Biological: VH4527079
Healthy adult participants receive a single dose of VH4527079 Dose 5 (high dose) by IV infusion.
Biological: VH4527079
Healthy adult participants receive a single dose of VH4527079 Dose 6 (max dose) by IV infusion.
Biological: VH4527079
Healthy adult participants receive a single dose of VH4527079 Dose 1 (lowest dose) by SC injection.
Biological: VH4527079
Healthy adult participants receive three doses of VH4527079 dose that is selected in Arm A, by IV infusion, separated by a time interval.
Biological: VH4527079
Participants with HIV receive three doses of VH4527079 dose that is selected in Arm A, by IV infusion, separated by a time interval.
Biological: VH4527079
VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
Number of participants with adverse events (AEs) of Grade 2 and above severity
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity of AEs will be assessed using Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life threatening and Grade 5=Death.
Time frame: Up to Week 24 follow-up period
Area under the plasma-concentration time curve from time zero to infinity (AUC 0-inf) of VH4527079
Time frame: From Day 1 Up to Week 24 follow-up period
Area under the plasma-concentration time curve from time zero to the last quantifiable concentration (AUC 0-tlast) of VH4527079
Time frame: From Day 1 Up to Week 24 follow-up period
Area under the plasma-concentration time curve from defined interval between doses (AUCtau) of VH4527079
Time frame: From Day 1 Up to Week 24 follow-up period
Maximum observed plasma concentration (Cmax) of VH4527079
Time frame: From Day 1 Up to Week 24 follow-up period
Time to maximum observed plasma concentration (Tmax) of VH4527079
Time frame: From Day 1 Up to Week 24 follow-up period
Apparent terminal half-life (t1/2) of VH4527079
Time frame: From Day 1 Up to Week 24 follow-up period
AUC0-inf of VH4527079 after a single dose administered via SC route relative to IV administration
Time frame: From Day 1 Up to Week 24 follow-up period
AUC0-tlast of VH4527079 after a single dose administered via SC route relative to IV administration
Time frame: From Day 1 Up to Week 24 follow-up period
Cmax of VH4527079 after a single dose administered via SC route relative to IV administration
Time frame: From Day 1 Up to Week 24 follow-up period
Post-baseline values for chemistry panels: Glucose (fasting), Blood Urea Nitrogen, Creatinine, Calcium, Magnesium, Potassium, Phosphate, Direct Bilirubin, Total Bilirubin & Fasting lipid panel (milligrams per deciliter)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for chemistry panels: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per liter)
Chemistry panels included Aspartate aminotransferase (AST)/ Serum glutamic-oxalo-acetic transaminase (SGOT), Alanine aminotransferase (ALT)/ Serum glutamic-pyruvic transaminase (SGPT), Alkaline phosphatase (ALP) and Creatinine phosphokinase (CPK)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for chemistry panels: Amylase and Lipase (fasting) (Units per Liter)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for chemistry panels: Total Protein (Grams per deciliter)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for chemistry panels: Sodium chloride and Bicarbonate (milliequivalents per liter)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for hematology panels: Platelet count (cells per microliter)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for hematology panels: Red Blood Cell (RBC) Count (million cells per microliter)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for hematology panels: Hemoglobin (Hgb) (grams per deciliter)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for hematology panels: Hematocrit (Proportion of red blood cells in blood)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for hematology panels: Mean Corpuscular Volume (MCV) (Femtoliters)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for hematology panels: Mean Corpuscular Hemoglobin (MCH) (Picograms)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for hematology panels: Reticulocytes (Percentage of reticulocytes)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for hematology panels: Differential count of Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per liter)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for coagulation panels: Prothrombin time (PT) and Partial Thromboplastin Time (PTT) (Seconds)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Post-baseline values for coagulation panels: International normalized ratio (INR) (Ratio)
Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period
Change from baseline values for chemistry panels: Glucose (fasting), Blood Urea Nitrogen, Creatinine, Calcium, Magnesium, Potassium, Phosphate, Direct Bilirubin, Total Bilirubin and Fasting lipid panel (milligrams per deciliter)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for chemistry panels: AST/ SGOT, ALT/ SGPT, ALP and CPK (International Units per liter)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for chemistry panels: Amylase and Lipase (fasting) (Units per Liter)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for chemistry panels: Total Protein (Grams per deciliter)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for chemistry panels: Sodium chloride and Bicarbonate (milliequivalents per liter)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for hematology panels: Platelet count (cells per microliter)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for hematology panels: RBC Count (million cells per microliter)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for hematology panels: Hgb (grams per deciliter)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for hematology panels: Hematocrit (Proportion of red blood cells in blood)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for hematology panels: MCV (Femtoliters)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for hematology panels: MCH (Picograms)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for hematology panels: Reticulocytes (Percentage of reticulocytes)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for hematology panels: Differential count of Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per liter)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for coagulation panels: PT and PTT (Seconds)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Change from baseline values for coagulation panels: INR (Ratio)
Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period
Number of participants with maximum post-baseline QT interval corrected (QTc) values compared to baseline by category
QTc values will be categorized as no change= number of participants with QTc values less than or equal to (\<=)450 milliseconds (msec), any increase= number of participants with QTc values more than (\>)450 - 480 msec, number of participants with QTc values \>480 -500 msec, and number of participants with QTc values \>500 msec
Time frame: Up to Week 24 follow-up period
Number of participants with maximum post-baseline increases in QTc values compared to baseline by category
Post-baseline increase in QTc values will be categorized by number of participants with QTc value increase of \<=30 msec, number of participants with QTc value increase of 31 - 60 msec, and number of participants with QTc value increase of \>60 msec
Time frame: Up to Week 24 follow-up period
Number of participants with worst case post-baseline values relative to potential clinical importance criteria compared to baseline for diastolic and systolic blood pressure
Number of participants with post-baseline changes will be categorized as change to low, change to within range or no change, and change to high
Time frame: Up to Week 24 follow-up period
Number of participants with worst case post-baseline values relative to potential clinical importance criteria compared to baseline for pulse rate
Number of participants with post-baseline changes will be categorized as change to low, change to within range or no change, and change to high
Time frame: Up to Week 24 follow-up period
Number of participants with any AEs and AEs by severity
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity of AEs will be assessed using Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life threatening and Grade 5=Death.
Time frame: Up to Week 24 follow-up period
Number of participants who discontinue treatment due to AEs
Time frame: Up to Week 24 follow-up period
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.viiv-studyregister.com
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Sep 2026, 23 months.
How these figures are worked out, and which studies are left out of them.
Terminated for business reasons
Terminated for business reasons
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.